Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Senior Scientific's nanomagnetic technology more sensitive in detecting breast cancer

Manhattan Scientifics announced today that "Breast Cancer Research," an international, peer-reviewed online journal, has published results of a study using Senior Scientific's nanomagnetic technology.

1 Nov 2011

New method can reduce intrusive thoughts in men with prostate cancer

Men with prostate cancer are twice as likely to commit suicide, but a method where they put intrusive thoughts into words may reduce this risk, reveals research at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

1 Nov 2011

NCI awards ImaginAb $2.3M grant to develop PET diagnostic imaging agents

ImaginAb, Inc. is pleased to announce that it has been awarded a total of $2.3 million in funding from the National Cancer Institute's Small Business Innovation Research program to help further develop diagnostic imaging agents for Positron Emission Tomography.

1 Nov 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

31 Oct 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.

31 Oct 2011

The West Clinic to partner with Methodist for cancer care

Methodist Healthcare and The West Clinic have entered into a partnership, effective January 1, 2012, to transform cancer care in the Mid-South area. The West Clinic, the region's premier cancer practice and a nationally-recognized leader in cancer research, is joining forces with Methodist to create a comprehensive, fully integrated cancer service for the benefit of Mid-South residents.

29 Oct 2011

BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment

ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

29 Oct 2011

NHS must plan to deal with predicted 45% leap in new cancer cases

The NHS must start planning now to deal with a predicted leap of 45 per cent in the number of new cancer cases in the UK over the next two decades, Cancer Research UK warns today (Friday).

28 Oct 2011

New England Journal of Medicine weighs in with views on PSA testing

In four articles in the respected medical journal, doctors assess the recent change in guidelines on screening for prostate cancer in men.

28 Oct 2011

Viewpoints: The health law and Wal-Mart; congressional probe into Planned Parenthood; trimming Medicare

When Wal-Mart endorsed President Obama's health care plan in 2009, CEO Mike Duke said it did so "to remove the burden that is crushing America's businesses and hampering our competitiveness in the global economy." That doesn't seem to be working out too well - for all Americans, and especially for Wal-Mart's employees.

27 Oct 2011

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

PSA test predicts biopsy need and prostate cancer development

The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. The findings were released today during a meeting of the North Central Section of the American Urological Association in Rancho Mirage, Calif.

22 Oct 2011

New mathematical models can predict prostate cancer aggressiveness

Alexander R. A. Anderson, Ph.D., co-director of Integrative Mathematical Oncology (IMO) at Moffitt Cancer Center, and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University and Gustavo Ayala, M.D., at Baylor College of Medicine, have received a five-year, $3 million grant from the National Institutes of Health to create new mathematical models to predict prostate cancer aggressiveness.

22 Oct 2011

Learning about politics in the midst of screening recommendations

The recent recommendation by the U.S. Preventive Services Task Force that women get less frequent screenings for cervical cancer demonstrated a remarkably different response than other such recommendations.

22 Oct 2011

C-11 choline PET/CT scans can be utilized as prostate cancer staging tool

Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be utilized as a staging and potentially therapeutic tool in prostate cancer.

22 Oct 2011

AAHPO honors BMC physician for medical contributions in the U.S., Armenia

Richard Babayan, MD, was honored recently by the Armenian American Health Professional Organization (AAHPO) for his exceptional contributions to medicine in both the United States and in Armenia.

21 Oct 2011

TJUH offers new optical imaging agent for bladder cancer detection

Thomas Jefferson University Hospital is one of a select number of medical centers nationwide—and currently the only one in the Northeast—offering a newly approved optical imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer.

21 Oct 2011

OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer

OncoGenex Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer.

21 Oct 2011

Older men more likely to die from prostrate cancer

Contrary to common belief, men age 75 and older are diagnosed with late-stage and more aggressive prostate cancer and thus die from the disease more often than younger men, according to a University of Rochester analysis published online this week by the journal, Cancer.

20 Oct 2011